<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5764337</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0190877</article-id><article-id pub-id-type="publisher-id">PONE-D-17-24364</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA recombination</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA recombination</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Replication</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Amino Acid Substitution</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Amino Acid Substitution</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Amino Acid Substitution</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Enzymology</subject><subj-group><subject>Enzyme Kinetics</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010&#x02013;2015</article-title><alt-title alt-title-type="running-head">Susceptibility and kinetics of Thai influenza viruses</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tewawong</surname><given-names>Nipaporn</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marathe</surname><given-names>Bindumadhav M.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Poovorawan</surname><given-names>Yong</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vongpunsawad</surname><given-names>Sompong</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Webby</surname><given-names>Richard J.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9067-5682</contrib-id><name><surname>Govorkova</surname><given-names>Elena A.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Infectious Diseases, St. Jude Children&#x02019;s Research Hospital, Memphis, Tennessee, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Tompkins</surname><given-names>Stephen Mark</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Georgia, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The NAIs oseltamivir carboxylate (oseltamivir) and zanamivir were provided by Hoffmann-La Roche, Ltd. (Basel, Switzerland). The NAI peramivir was provided by BioCryst Pharmaceuticals (Birmingham, AL). There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.</p></fn><corresp id="cor001">* E-mail: <email>elena.govorkova@stjude.org</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>1</issue><elocation-id>e0190877</elocation-id><history><date date-type="received"><day>27</day><month>6</month><year>2017</year></date><date date-type="accepted"><day>21</day><month>12</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Tewawong et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Tewawong et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0190877.pdf"/><abstract><p>Amino acid substitutions within or near the active site of the viral neuraminidase (NA) may affect influenza virus fitness. In influenza A(H3N2) and B viruses circulating in Thailand between 2010 and 2015, we identified several NA substitutions that were previously reported to be associated with reduced inhibition by NA inhibitors (NAIs). To study the effect of these substitutions on the enzymatic properties of NA and on virus characteristics, we generated recombinant influenza viruses possessing either a wild type (WT) NA or an NA with a single I222V, S331G, or S331R substitution [in influenza A(H3N2) viruses] or a single D342S, A395T, A395V, or A395D NA substitution (in influenza B viruses). We generated recombinant (7:1) influenza A and B viruses on the genetic background of A/Puerto Rico/8/1934 (A/PR/8, H1N1) or B/Yamanashi/166/1998 (B/YAM) viruses, respectively. In contrast to the expected phenotypes, all the recombinant influenza A(H3N2) and B viruses carrying putative NA resistance substitutions were susceptible to NAIs. The <italic>K</italic><sub>m</sub> and <italic>V</italic><sub>max</sub> for the NAs of A/PR8-S331G and A/PR8-S331R viruses were higher than for the NA of WT virus, and the corresponding values for the B/YAM-D342S virus were lower than for the NA of WT virus. Although there was initial variation in the kinetics of influenza A and B viruses&#x02019; replication in MDCK cells, their titers were comparable to each other and to WT viruses at later time points. All introduced substitutions were stable except for B/YAM-D342S and B/YAM-A395V which reverted to WT sequences after three passages. Our data suggest that inferring susceptibility to NAIs based on sequence information alone should be cautioned. The impact of NA substitution on NAI resistance, viral growth, and enzymatic properties is viral context dependent and should be empirically determined.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006492</institution-id><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>HHSN272201400006C</award-id><principal-award-recipient><name><surname>Webby</surname><given-names>Richard J.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>National Science and Technology Development Agency Thailand</institution></funding-source><award-id>P-15-50004</award-id><principal-award-recipient><name><surname>Poovorawan</surname><given-names>Yong</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>The Center of Excellence in Clinical Virology of Chulalongkorn University</institution></funding-source><award-id>GCE 59-009-30-005</award-id><principal-award-recipient><name><surname>Poovorawan</surname><given-names>Yong</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>Overseas Research Experience Scholarship for Graduate Students of Chulalongkorn University</institution></funding-source><principal-award-recipient><name><surname>Tewawong</surname><given-names>Nipaporn</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the following funding sources: The National Institute of Allergy and Infectious Diseases, National Institutes of Health, Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract no. HHSN272201400006C to Richard J. Webby, the American Lebanese Syrian Associated Charities (ALSAC), The Research Chair Grant from the National Science and Technology Development Agency (P-15-50004) to Yong Poovorawan, and The Center of Excellence in Clinical Virology of Chulalongkorn University (GCE 59-009-30-005) to Yong Poovorawan. Nipaporn Tewawong received the Overseas Research Experience Scholarship for Graduate Students of Chulalongkorn University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Influenza A and B viruses are important human respiratory pathogens that cause annual epidemics worldwide. Anti-influenza prophylaxis and treatment with antiviral drugs are used to prevent and control influenza virus infections, particularly when vaccines are ineffective or unavailable [<xref rid="pone.0190877.ref001" ref-type="bibr">1</xref>]. The Centers for Diseases Control and Prevention (CDC) has reported high levels of resistance (&#x0003e;99%) to adamantanes among circulating seasonal influenza A(H3N2) and pandemic A(H1N1)pdm09 viruses [<xref rid="pone.0190877.ref002" ref-type="bibr">2</xref>]. Therefore, existing options for the prophylaxis and treatment of influenza virus infection are limited to a single class of antiviral drug, neuraminidase inhibitors (NAIs). Three NAIs, namely oral oseltamivir, inhaled zanamivir, and intravenous peramivir, are approved by the United States Food and Drug Administration and are recommended for the prophylaxis and treatment of patients infected with influenza A or B viruses [<xref rid="pone.0190877.ref002" ref-type="bibr">2</xref>].</p><p>The influenza neuraminidase (NA) is a tetrameric type II integral membrane protein with sialidase activity that is responsible for releasing newly produced viral particles from virus-infected cells [<xref rid="pone.0190877.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0190877.ref004" ref-type="bibr">4</xref>]. Based on their sequences, the NA genes of influenza viruses are classified as group 1 (N1, N4, N5, and N8), group 2 (N2, N3, N6, N7, N9) and influenza B NA [<xref rid="pone.0190877.ref005" ref-type="bibr">5</xref>]. In influenza A and B viruses, the NA active site is formed by highly conserved framework (E119, R156, W178, S179, D/N198, I222, E227, H274, E277, N294, and E425 [in N2 numbering]) and catalytic (R118, D151, R152, R224, E276, R292, R371, and Y406) residues [<xref rid="pone.0190877.ref006" ref-type="bibr">6</xref>&#x02013;<xref rid="pone.0190877.ref008" ref-type="bibr">8</xref>]. NA amino acid substitutions located within or in close proximity to the NA active site can result in reduced inhibition of influenza viruses by NAIs and may affect the NA enzymatic properties, replication efficiency, transmissibility, and fitness of the virus <italic>in vitro</italic> and <italic>in vivo</italic> [<xref rid="pone.0190877.ref009" ref-type="bibr">9</xref>&#x02013;<xref rid="pone.0190877.ref012" ref-type="bibr">12</xref>]. The various NA-subtype specific substitutions arise as a result of selection by different NAIs, and can be detected with different frequencies in clinical samples or in surveillance studies [<xref rid="pone.0190877.ref012" ref-type="bibr">12</xref>]. Although substitutions have been reported at novel residues in NAs, the effect of these substitutions on the NAI susceptibility of viruses with different genetic backgrounds is largely undetermined. Substitutions at residue 222 (T/V/M/L) conferred reduced susceptibility to NAIs and were found in seasonal A(H1N1), A(H1N1)pdm09, and highly pathogenic influenza A(H5N1) viruses. I222T/V NA substitutions were reported to cause reduced susceptibility of A(H5N1) viruses to NAIs, with 60- to 105-fold higher IC<sub>50</sub>s to oseltamivir when compared to the wild-type NAs [<xref rid="pone.0190877.ref013" ref-type="bibr">13</xref>]. Antiviral surveillance studies identified novel NA substitutions (S331R in influenza A(H3N2) viruses; D342S and A395E in influenza B viruses) that were associated with reduced inhibition by oseltamivir and peramivir (as indicated by higher IC<sub>50</sub> values for these compounds) [<xref rid="pone.0190877.ref014" ref-type="bibr">14</xref>&#x02013;<xref rid="pone.0190877.ref017" ref-type="bibr">17</xref>]. These substitutions were located outside the NA active site [<xref rid="pone.0190877.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0190877.ref015" ref-type="bibr">15</xref>]. A recent study demonstrated that an influenza A(H1N1)pdm09 variant containing double NA substitution at residues I427T/Q313R outside the NA active site had decreased NAI susceptibility, with altered NA properties and viral fitness [<xref rid="pone.0190877.ref018" ref-type="bibr">18</xref>].</p><p>Previously, we reported substitutions at residues 222 and 331 in the NA of influenza A(H3N2) viruses and at residues 342 and 395 in that of influenza B viruses circulating in Thailand [<xref rid="pone.0190877.ref019" ref-type="bibr">19</xref>]. However, the effect of these NA substitutions on the susceptibility to NAIs, the enzymatic properties, and the fitness of the viruses were not determined. Here, we applied reverse genetics and generated recombinant influenza A and B viruses possessing either wild-type (WT) NA or an NA with a single I222V, S331G, or S331R substitution [in influenza A(H3N2) viruses] or a single S342S, A395T, A395V, or A395S substitution [in influenza B viruses].We then used these recombinant viruses to study the properties (activity, enzyme kinetic, thermostability) of their NAs, their susceptibility to NAIs, their replication kinetics, and the genetic stability of the NA substitutions during passages in MDCK cells.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Clinical samples, influenza viruses, and cells</title><p>The novel NA substitutions were identified in influenza A(H3N2) and B viruses in polymerase chain reaction (PCR)-positive respiratory samples from patients in Thailand (<bold><xref ref-type="table" rid="pone.0190877.t001">Table 1</xref></bold>) [<xref rid="pone.0190877.ref019" ref-type="bibr">19</xref>]. Substitution-encoding NA gene sequences were amplified from these samples, which were obtained from the Center of Excellence in Clinical Virology at Chulalongkorn University in Thailand as part of the influenza surveillance program. The study protocol was approved by the Institutional Review Board (IRB) of the Faculty of Medicine at Chulalongkorn University (IRB No. 581/58). The study was conducted according to the ethical principles regarding human experimentation set out in the Declaration of Helsinki, and the IRB waived the need for consent because the samples were de-identified and anonymous.</p><table-wrap id="pone.0190877.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0190877.t001</object-id><label>Table 1</label><caption><title>Novel NA substitutions in influenza A(H3N2) and B PCR-positive samples from Thailand used in the study.</title></caption><alternatives><graphic id="pone.0190877.t001g" xlink:href="pone.0190877.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Influenza virus</th><th align="center" rowspan="1" colspan="1">Subtype/lineage</th><th align="center" rowspan="1" colspan="1">Substitution in NA<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></th><th align="center" rowspan="1" colspan="1">Recombinant influenza virus<xref ref-type="table-fn" rid="t001fn002"><sup>b</sup></xref></th><th align="center" rowspan="1" colspan="1">Accession no.<xref ref-type="table-fn" rid="t001fn003"><sup>c</sup></xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">A/Thailand/CU-B11870/2015</td><td align="center" rowspan="1" colspan="1">H3N2</td><td align="center" rowspan="1" colspan="1">Wild-type</td><td align="center" rowspan="1" colspan="1">A/PR8-WT</td><td align="center" rowspan="1" colspan="1">KX151204</td></tr><tr><td align="left" rowspan="1" colspan="1">A/Thailand/CU-B7418/2013</td><td align="center" rowspan="1" colspan="1">H3N2</td><td align="center" rowspan="1" colspan="1">I222V</td><td align="center" rowspan="1" colspan="1">A/PR8-I222V</td><td align="center" rowspan="1" colspan="1">KP336079</td></tr><tr><td align="left" rowspan="1" colspan="1">A/Thailand/CU-B11518/2015</td><td align="center" rowspan="1" colspan="1">H3N2</td><td align="center" rowspan="1" colspan="1">S331G</td><td align="center" rowspan="1" colspan="1">A/PR8-S331G</td><td align="center" rowspan="1" colspan="1">KX151190</td></tr><tr><td align="left" rowspan="1" colspan="1">A/Thailand/CU-B12139/2015</td><td align="center" rowspan="1" colspan="1">H3N2</td><td align="center" rowspan="1" colspan="1">S331R</td><td align="center" rowspan="1" colspan="1">A/PR8-S331R</td><td align="center" rowspan="1" colspan="1">KX151213</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Thailand/CU-B11776/2015</td><td align="center" rowspan="1" colspan="1">B/Yam</td><td align="center" rowspan="1" colspan="1">D342S</td><td align="center" rowspan="1" colspan="1">B/YAM-D342S</td><td align="center" rowspan="1" colspan="1">KX151370</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Thailand/CU-B5910/2011</td><td align="center" rowspan="1" colspan="1">B/Vic</td><td align="center" rowspan="1" colspan="1">A395T</td><td align="center" rowspan="1" colspan="1">B/YAM-A395T</td><td align="center" rowspan="1" colspan="1">JX513088</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Thailand/CU-H3002/2011</td><td align="center" rowspan="1" colspan="1">B/Vic</td><td align="center" rowspan="1" colspan="1">A395D</td><td align="center" rowspan="1" colspan="1">B/YAM-A395D</td><td align="center" rowspan="1" colspan="1">JX513200</td></tr><tr><td align="left" rowspan="1" colspan="1">B/Thailand/CU-B10236/2014</td><td align="center" rowspan="1" colspan="1">B/Vic</td><td align="center" rowspan="1" colspan="1">A395V</td><td align="center" rowspan="1" colspan="1">B/YAM-A395V</td><td align="center" rowspan="1" colspan="1">KX151337</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><sup>a</sup> Numbering is based on an alignment of NAs from the following reference strains: A/Perth/16/2009 (H3N2) and B/Yamanashi/166/1998.</p></fn><fn id="t001fn002"><p><sup>b</sup> Designations of recombinant influenza viruses used in the study.</p></fn><fn id="t001fn003"><p><sup>c</sup> GenBank database accession numbers for the NAs listed.</p></fn></table-wrap-foot></table-wrap><p>Influenza B/Brisbane/60/2008 (B/BR/60/08) virus was obtained from the repository at St. Jude Children&#x02019;s Research Hospital. Madin-Darby canine kidney (MDCK) cells (ATCC, Manassas, VA) were maintained in Eagle&#x02019;s Minimum Essential Medium supplemented with 5% fetal bovine serum and a mixture of antibiotics and antimycotics (100 U of penicillin, 0.1 mg of streptomycin, and 0.25 &#x003bc;g of amphotericin B/mL). Human embryonic kidney 293T cells (ATCC, Manassas, VA) were maintained in Opti-MEM reduced-serum medium with GlutaMAX supplement at a final concentration of 2 mM (Life Technologies, Gaithersburg, MD) and no antibiotics.</p></sec><sec id="sec004"><title>Cloning of NA into pHW2000 and pAD3000 plasmids</title><p>Influenza viral RNA was extracted using a RNeasy Kit (Qiagen, CA). The full-length NA genes (numbering is based on an alignment of NAs from the following reference strains: A/Perth/16/2009 (H3N2) and B/Yamanashi/166/1998 [<xref rid="pone.0190877.ref020" ref-type="bibr">20</xref>]) of influenza A(H3N2) and B viruses were amplified by one-step RT-PCR with primers previously described for the NA segments of influenza A [<xref rid="pone.0190877.ref021" ref-type="bibr">21</xref>] and B [<xref rid="pone.0190877.ref022" ref-type="bibr">22</xref>] viruses. PCR products were gel-purified (QIAquick Gel Extraction Kit, Qiagen) and then digested with <italic>Bsa</italic>I [<xref rid="pone.0190877.ref021" ref-type="bibr">21</xref>] or <italic>Bsm</italic>BI [<xref rid="pone.0190877.ref022" ref-type="bibr">22</xref>] restriction enzymes (New England Biolabs, Boston, MA). The plasmid vectors were digested with <italic>Bsm</italic>BI, and the NA segments were ligated with T4 DNA ligase (New England Biolabs, Boston, MA) into pHW2000 (for influenza A NAs) or pAD3000 (for influenza B NAs).</p><p>Plasmids were transformed into One Shot chemically competent Escherichia coli cells (Invitrogen, Carlsbad, CA), and positive clones were inoculated into Terrific Broth medium containing ampicillin. The positive clones were purified using HiSpeed Plasmid Maxi Kits (Qiagen, CA), and the plasmid DNA concentrations were determined by both UV spectrophotometry at 260 nm and analysis on agarose gels. The constructed plasmids were sequenced to ensure their identity with the field strains.</p></sec><sec id="sec005"><title>Generation of recombinant influenza A and B viruses</title><p>Recombinant (7:1) influenza viruses carrying NAs of influenza A(H3N2) or B viruses circulating in Thailand (<xref ref-type="table" rid="pone.0190877.t001">Table 1</xref>) were generated on a homogenous genetic background of A/Puerto Rico/8/1934 (H1N1) (A/PR8) and B/Yamanashi/166/1998 (B/YAM) influenza viruses, respectively. The A/PR8-WT was a 7:1 reassortant with the N2 NA of A/Thailand/CU-B11870/2015 in a background of A/PR8 (<xref ref-type="table" rid="pone.0190877.t001">Table 1</xref>). The eight plasmids were transfected into 293T cells as previously described [<xref rid="pone.0190877.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0190877.ref023" ref-type="bibr">23</xref>]. The NA gene segment was amplified from the extracted viral RNA of rescued viruses by using one-step RT-PCR. The NAs of recombinant viruses were sequenced by the Hartwell Center for Bioinformatics and Biotechnology at St. Jude Children&#x02019;s Research Hospital, using BigDye Terminator (version 3) chemistry and synthetic oligonucleotides. Samples were analyzed on Applied Biosystems 3700 DNA analyzers. The NA sequences were analyzed with SeqMan software (DNAStar, Madison, WI). Recombinant viruses were grown in the allantoic cavity of 10-day-old embryonated chicken eggs (Marshall Durbin, Birmingham, AL) for 72 h at 35&#x000b0;C (for influenza A viruses) or 33&#x000b0;C (for influenza B viruses). The virus-containing allantoic fluid was stored at &#x02212;80&#x000b0;C until use. The 50% tissue culture infectious dose (TCID<sub>50</sub>) of each recombinant influenza virus was determined in MDCK cells incubated for 72 h at 35&#x000b0;C (for influenza A viruses) or 33&#x000b0;C (for influenza B viruses). The TCID<sub>50</sub> values were calculated by the Reed-Muench method [<xref rid="pone.0190877.ref024" ref-type="bibr">24</xref>]. The HA titers were determined by using packed chicken red blood cells diluted to a hematocrit of 0.5%.</p></sec><sec id="sec006"><title>NAI susceptibility</title><p>The NAIs (oseltamivir carboxylate, zanamivir, and peramivir) were dissolved in sterile distilled water, and aliquots were stored at &#x02212;20&#x000b0;C until use. A fluorescence-based NA inhibition assay with the fluorogenic substrate 2&#x02032;-(4-methylumbelliferyl)-&#x003b1;-D-N-acetylneuraminic acid (MUNANA; Sigma-Aldrich, St Louis, MO) was used to determine the 50% inhibitory concentration (IC<sub>50</sub>) values [<xref rid="pone.0190877.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0190877.ref026" ref-type="bibr">26</xref>]. Briefly, viruses were standardized to equivalent NA enzyme activity in the linear range of the curve and were mixed with various concentrations of NAI (ranged from 0.05 to 5000 nM in the final reaction mixture) in 96-well flat-bottom black opaque plates (Corning Costar, NY). The virus-NAI mixture was incubated at 37&#x000b0;C for 30 min prior to the addition of MUNANA and then incubated with substrate (100 &#x003bc;M final concentration) at 37&#x000b0;C for 30 min. The reaction was terminated by the addition of the stop solution (0.1 M glycine in 25% ethanol, pH 10.7). Fluorometric determinations were quantified with a Synergy 2 multi-mode microplate reader (BioTek Instruments, Winooski, VT) based on the release of the fluorescent product 4-methylumbelliferone (4-MU) using excitation and emission wavelengths of 360 and 460 nm, respectively. The IC<sub>50</sub>s of viruses were determined using the curve-fitting model in GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). The phenotypic NAI susceptibility of influenza A and B viruses was evaluated based on the fold change in their IC<sub>50</sub> values when compared to those of susceptible viruses from the same NA subtype/lineage, as previously described by the WHO Influenza Antiviral Working Group [<xref rid="pone.0190877.ref014" ref-type="bibr">14</xref>]. The inhibition was categorized as &#x0201c;normal&#x0201d; (a &#x02264; 10-fold change for influenza A and a &#x02264; 5-fold change for influenza B viruses); &#x0201c;reduced&#x0201d; (a 10&#x02013;100-fold change for influenza A and a 5&#x02013;50-fold change for influenza B viruses); or &#x0201c;highly reduced&#x0201d; (a &#x02265; 100-fold change for influenza A and a &#x02265; 50-fold change for influenza B viruses).</p></sec><sec id="sec007"><title>NA enzyme activity and thermostability</title><p>The NA activity of recombinant viruses was measured by a fluorometric assay with MUNANA substrate as described above [<xref rid="pone.0190877.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0190877.ref026" ref-type="bibr">26</xref>]. The NA activity was normalized against the amount of infectious virus and presented as the quantity of 4-MU (in &#x003bc;g) formed per 1 log<sub>10</sub>TCID<sub>50</sub> of the virus. The thermostability of the NA was determined by incubating viruses in a gradient thermocycler at 33, 37, 45, or 55&#x000b0;C for 15 or 30 min, then all viruses were brought to room temperature, and NA activity was subsequently measured [<xref rid="pone.0190877.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0190877.ref026" ref-type="bibr">26</xref>]. The NA activity was determined and expressed as a percentage of the NA activity of the virus at 4&#x000b0;C (unheated). The NA activity of each virus was calculated based on the mean of triplicate assays.</p></sec><sec id="sec008"><title>NA enzyme kinetics assay</title><p>The enzyme kinetics (<italic>V</italic><sub>max</sub> and <italic>K</italic><sub>m</sub>) of the NAs of recombinant influenza A and B viruses with a single NA amino acid substitution were determined as previously described [<xref rid="pone.0190877.ref027" ref-type="bibr">27</xref>]. First, the optimum dilution of recombinant virus to assess NA kinetic properties was determined. Briefly, 2-fold virus dilutions were incubated with the MUNANA substrate (100 &#x003bc;M), and NA activity was measured every 60 s for 60 min to identify virus dilution within a linear range of the curve that converts &#x02264; 15% of the total amount of MUNANA substrate and signal to noise ration &#x0003e; 10 across most of time course. We then measured the NA enzyme kinetics at pH 6.5 with enzyme buffer and a final concentration of MUNANA substrate ranging from 0.98 to 1000 &#x003bc;M. The reaction was monitored at 37&#x000b0;C in a total volume of 150 &#x003bc;L, and the fluorescence signal was detected every 60 s for 60 min using excitation and emission wavelengths of 360 and 460 nm, respectively. The MUNANA substrate affinity (<italic>K</italic><sub>m</sub>) and velocity of catalysis (<italic>V</italic><sub>max</sub>) values were calculated by fitting appropriate Michaelis-Menten equations to the data by using nonlinear regression in GraphPad Prism 5 software.</p></sec><sec id="sec009"><title>Replication kinetics</title><p>Multi-step growth curves were determined for each recombinant influenza virus in MDCK cells. Confluent cell monolayers were infected with recombinant virus at a multiplicity of infection (MOI) of 1 or 0.001 TCID<sub>50</sub>/cell. The supernatant was collected at 6, 12, and 24 h (for an MOI of 1 TCID<sub>50</sub>/cell) and at 24, 48, and 72 h (for an MOI of 0.001 TCID<sub>50</sub>/cell) after virus inoculation and stored at &#x02212;70&#x000b0;C until use. Virus titers were determined by TCID<sub>50</sub> assays in MDCK cells.</p></sec><sec id="sec010"><title>Statistical analysis</title><p>The NA activity, IC<sub>50</sub> values, enzyme kinetic parameters (<italic>K</italic><sub>m</sub> and <italic>V</italic><sub>max</sub>), and virus titers were compared by two-tailed Student&#x02019;s <italic>t</italic>-tests. The results were considered significantly different if the <italic>P</italic>-value was less than 0.05.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>NAI susceptibility profiles</title><p>We used NA inhibition assays to determine the NAI susceptibility profiles of 7:1 recombinant influenza A and B viruses carrying single NA amino acid substitutions (<bold><xref ref-type="table" rid="pone.0190877.t002">Table 2</xref></bold>). When compared to the IC<sub>50</sub> value of the A/PR8-WT virus, the fold changes in the IC<sub>50</sub> values of recombinant influenza A viruses were &#x0003e; 10-fold. These results demonstrated that A/PR8 viruses carrying NA from A(H3N2) virus with single I222V, S331R, or S331G NA substitutions were susceptible to NAIs. For the recombinant B/YAM viruses, the fold changes in the IC<sub>50</sub> values were &#x0003e; 5-fold when compared to the IC<sub>50</sub> of the B/BR/60/08 virus. These results revealed that B/YAM viruses carrying NAs from currently circulating influenza B viruses with single D342S, A395T, A395V, or A395D NA substitutions were susceptible to NAIs.</p><table-wrap id="pone.0190877.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0190877.t002</object-id><label>Table 2</label><caption><title>NAI susceptibility profiles for recombinant influenza A and B viruses carrying a single NA substitution.</title></caption><alternatives><graphic id="pone.0190877.t002g" xlink:href="pone.0190877.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Recombinant influenza virus</th><th align="center" colspan="3" rowspan="1">NA enzyme inhibition assay (mean IC<sub>50</sub> &#x000b1; SD, nM)<xref ref-type="table-fn" rid="t002fn001"><sup>a</sup></xref></th></tr><tr><th align="center" rowspan="1" colspan="1">Oseltamivir<break/>carboxylate</th><th align="center" rowspan="1" colspan="1">Zanamivir</th><th align="center" rowspan="1" colspan="1">Peramivir</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1"><italic>Influenza A viruses</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-WT</td><td align="center" rowspan="1" colspan="1">0.3 &#x000b1; 0.0 (1)</td><td align="center" rowspan="1" colspan="1">0.4 &#x000b1; 0.1 (1)</td><td align="center" rowspan="1" colspan="1">0.1 &#x000b1; 0.02 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-I222V</td><td align="center" rowspan="1" colspan="1">0.3 &#x000b1; 0.1 (1)</td><td align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.1 (1.3)</td><td align="center" rowspan="1" colspan="1">0.1 &#x000b1; 0.01 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-S331G</td><td align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.5 (1.6)</td><td align="center" rowspan="1" colspan="1">0.4 &#x000b1; 0.1 (1)</td><td align="center" rowspan="1" colspan="1">0.3 &#x000b1; 0.3 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-S331R</td><td align="center" rowspan="1" colspan="1">0.1 &#x000b1; 0.1 (0.3)</td><td align="center" rowspan="1" colspan="1">0.4 &#x000b1; 0.1 (1)</td><td align="center" rowspan="1" colspan="1">0.2 &#x000b1; 0.06 (2)</td></tr><tr><td align="left" colspan="4" rowspan="1"><italic>Influenza B viruses</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">B/BR/60/08</td><td align="center" rowspan="1" colspan="1">16.1 &#x000b1; 7.8 (1)</td><td align="center" rowspan="1" colspan="1">3.0 &#x000b1; 0.6 (1)</td><td align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.33 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM- D342S</td><td align="center" rowspan="1" colspan="1">8.3 &#x000b1; 4.2 (0.5)</td><td align="center" rowspan="1" colspan="1">0.9 &#x000b1; 0.3 (0.3)</td><td align="center" rowspan="1" colspan="1">0.4 &#x000b1; 0.12 (0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395T</td><td align="center" rowspan="1" colspan="1">17.2 &#x000b1; 4.5 (1.1)</td><td align="center" rowspan="1" colspan="1">3.4 &#x000b1; 0.5 (1.1)</td><td align="center" rowspan="1" colspan="1">0.6 &#x000b1; 0.08 (1.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395D</td><td align="center" rowspan="1" colspan="1">12.3 &#x000b1; 2.7 (0.8)</td><td align="center" rowspan="1" colspan="1">2.5 &#x000b1; 0.5 (0.8)</td><td align="center" rowspan="1" colspan="1">0.5 &#x000b1; 0.36 (1)</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395V</td><td align="center" rowspan="1" colspan="1">18.3 &#x000b1; 7.2 (1.1)</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 0.3 (0.4)</td><td align="center" rowspan="1" colspan="1">0.8 &#x000b1; 0.12 (1.6)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><sup>a</sup> The IC<sub>50</sub> value is the concentration of NAI that inhibits viral NA activity by 50%. The values were obtained from three independent experiments. Data in parentheses represent the fold increase over the corresponding value for the A/PR8-WT or B/BR/60/08 viruses.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec013"><title>NA enzyme activity</title><p>We investigated the effect of NA amino acid substitutions on the NA activity of 7:1 recombinant influenza A and B viruses by using a modified fluorescence-based assay. The NA enzyme sialidase activity was standardized according to the amount of infectious virus (per 1 log<sub>10</sub>TCID<sub>50</sub>) and expressed as the quantity of 4-MU (in &#x003bc;g) (<bold><xref ref-type="table" rid="pone.0190877.t003">Table 3</xref></bold>). The NA substitutions at residue 331 (S331G and S331R) significantly decreased the NA activity of recombinant A/PR8 viruses as compared to that of A/PR8-WT NA (<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.001 and <italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01, respectively), whereas the I222V NA substitution slightly increased the NA activity (<bold><xref ref-type="table" rid="pone.0190877.t003">Table 3</xref></bold>). In contrast, the B/YAM-D342S and B/YAM-A395T viruses had significantly higher NA activity when compared to the reference B/BR/60/08 virus (<italic>P&#x02009;</italic>&#x0003c;&#x02009;0.01). The A395D substitution decreased the NA activity of recombinant B/YAM virus, whereas the A395V NA substitution increased the NA activity relative to that of the B/BR/60/08 virus (<bold><xref ref-type="table" rid="pone.0190877.t003">Table 3</xref></bold>). Thus, the S331G substitution had the greatest impact on the NA activity of recombinant A/PR8 viruses, followed by the S331R substitution, and the D342S and A395T substitutions had the greatest effect on the NA activity of recombinant B/YAM viruses.</p><table-wrap id="pone.0190877.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0190877.t003</object-id><label>Table 3</label><caption><title>NA activity and NA enzyme kinetics of recombinant influenza A and B viruses.</title></caption><alternatives><graphic id="pone.0190877.t003g" xlink:href="pone.0190877.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1"><break/>Recombinant influenza virus</th><th align="left" rowspan="2" colspan="1">Virus yield,<break/>MDCK cells<break/>(log<sub>10</sub>TCID<sub>50</sub>/mL)</th><th align="center" colspan="4" rowspan="1">NA enzymatic properties</th></tr><tr><th align="left" rowspan="1" colspan="1">NA activity<xref ref-type="table-fn" rid="t003fn001"><sup>a</sup></xref></th><th align="left" rowspan="1" colspan="1"><italic>K</italic><sub>m</sub> (&#x003bc;M)<xref ref-type="table-fn" rid="t003fn002"><sup>b</sup></xref></th><th align="left" rowspan="1" colspan="1"><italic>V</italic><sub>max</sub> (&#x003bc;M/min)<xref ref-type="table-fn" rid="t003fn002"><sup>b</sup></xref></th><th align="left" rowspan="1" colspan="1"><italic>V</italic><sub>max</sub> ratio<xref ref-type="table-fn" rid="t003fn003"><sup>c</sup></xref></th></tr></thead><tbody><tr><td align="left" colspan="6" rowspan="1"><italic>Influenza A viruses</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-WT</td><td align="center" rowspan="1" colspan="1">9.0 &#x000b1; 0.5</td><td align="center" rowspan="1" colspan="1">41.6 &#x000b1; 0.7</td><td align="center" rowspan="1" colspan="1">55.3 &#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">0.08 &#x000b1; 0.00</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-I222V</td><td align="center" rowspan="1" colspan="1">9.3 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">45.8 &#x000b1; 0.2</td><td align="center" rowspan="1" colspan="1">59.2 &#x000b1; 0.8</td><td align="center" rowspan="1" colspan="1">0.09 &#x000b1; 0.01</td><td align="center" rowspan="1" colspan="1">1.1</td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-S331G</td><td align="center" rowspan="1" colspan="1">8.3 &#x000b1; 0.4</td><td align="center" rowspan="1" colspan="1">4.3 &#x000b1; 0.6<xref ref-type="table-fn" rid="t003fn006">***</xref></td><td align="center" rowspan="1" colspan="1">71.7 &#x000b1; 1.1<xref ref-type="table-fn" rid="t003fn005">**</xref></td><td align="center" rowspan="1" colspan="1">0.14 &#x000b1; 0.00<xref ref-type="table-fn" rid="t003fn006">***</xref></td><td align="center" rowspan="1" colspan="1">1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-S331R</td><td align="center" rowspan="1" colspan="1">9.4 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">31.9 &#x000b1; 0.9<xref ref-type="table-fn" rid="t003fn005">**</xref></td><td align="center" rowspan="1" colspan="1">80.5 &#x000b1; 5.2<xref ref-type="table-fn" rid="t003fn005">**</xref></td><td align="center" rowspan="1" colspan="1">0.11 &#x000b1; 0.01<xref ref-type="table-fn" rid="t003fn005">**</xref></td><td align="center" rowspan="1" colspan="1">1.4</td></tr><tr><td align="left" colspan="6" rowspan="1"><italic>Influenza B viruses</italic></td></tr><tr><td align="left" rowspan="1" colspan="1">B/BR/60/08</td><td align="center" rowspan="1" colspan="1">5.6 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">30.2 &#x000b1; 3.0</td><td align="center" rowspan="1" colspan="1">20.3 &#x000b1; 1.1</td><td align="center" rowspan="1" colspan="1">0.09 &#x000b1; 0.01</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM- D342S</td><td align="center" rowspan="1" colspan="1">7.5 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">50.3 &#x000b1; 0.9<xref ref-type="table-fn" rid="t003fn005">**</xref></td><td align="center" rowspan="1" colspan="1">13.3 &#x000b1; 0.1<xref ref-type="table-fn" rid="t003fn005">**</xref></td><td align="center" rowspan="1" colspan="1">0.07 &#x000b1; 0.00<xref ref-type="table-fn" rid="t003fn004">*</xref></td><td align="center" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395T</td><td align="center" rowspan="1" colspan="1">7.5 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">58.2 &#x000b1; 0.5<xref ref-type="table-fn" rid="t003fn005">**</xref></td><td align="center" rowspan="1" colspan="1">17.8 &#x000b1; 0.4<xref ref-type="table-fn" rid="t003fn004">*</xref></td><td align="center" rowspan="1" colspan="1">0.08 &#x000b1; 0.00<xref ref-type="table-fn" rid="t003fn004">*</xref></td><td align="center" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395D</td><td align="center" rowspan="1" colspan="1">7.5 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">24.6 &#x000b1; 0.9</td><td align="center" rowspan="1" colspan="1">31.5 &#x000b1; 6.9</td><td align="center" rowspan="1" colspan="1">0.11 &#x000b1; 0.01</td><td align="center" rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395V</td><td align="center" rowspan="1" colspan="1">7.5 &#x000b1; 0.0</td><td align="center" rowspan="1" colspan="1">42.1 &#x000b1; 5.3</td><td align="center" rowspan="1" colspan="1">18.1 &#x000b1; 0.1</td><td align="center" rowspan="1" colspan="1">0.10 &#x000b1; 0.00</td><td align="center" rowspan="1" colspan="1">1.1</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><sup>a</sup> Values are the mean &#x000b1; SD from three independent experiments; they are expressed as the quantity of 4-MU (in &#x003bc;g) per 1 log<sub>10</sub>TCID<sub>50</sub> of the virus.</p></fn><fn id="t003fn002"><p><sup>b</sup> Values are the mean <italic>K</italic><sub>m</sub> and <italic>V</italic><sub>max</sub> from three independent experiments &#x000b1; SD.</p></fn><fn id="t003fn003"><p><sup>c</sup> Ratio of the <italic>V</italic><sub>max</sub> of the NA of the respective recombinant viruses to the <italic>V</italic><sub>max</sub> of the WT NA.</p></fn><fn id="t003fn004"><p>*<italic>P</italic> &#x0003c; 0.05</p></fn><fn id="t003fn005"><p>**<italic>P</italic> &#x0003c; 0.01; and</p></fn><fn id="t003fn006"><p>***<italic>P</italic> &#x0003c; 0.001 as compared to A/PR8-WT or B/BR/60/08 viruses, Student&#x02019;s <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec014"><title>NA enzyme kinetics</title><p>To investigate the effect of NA amino acid substitutions on NA enzymatic kinetics, we measured the <italic>K</italic><sub>m</sub> and <italic>V</italic><sub>max</sub> of NAs from recombinant influenza A and B viruses by using the fluorogenic MUNANA substrate (<bold><xref ref-type="table" rid="pone.0190877.t003">Table 3</xref></bold>). The <italic>K</italic><sub>m</sub> of A/PR8 virus NAs carrying S331G and S331R NA substitutions was significantly increased relative to that of WT NA (<italic>P</italic> &#x0003c; 0.01), whereas the D342S and A395T NA substitutions decreased the <italic>K</italic><sub>m</sub> of recombinant B/YAM viruses (<italic>P</italic> &#x0003c; 0.01 and <italic>P</italic> &#x0003c; 0.05, respectively). The S331G and S331R NA substitutions increased the <italic>V</italic><sub>max</sub> of recombinant influenza A virus NAs (<italic>P</italic> &#x0003c; 0.001 and <italic>P</italic> &#x0003c; 0.01, respectively) (<bold><xref ref-type="table" rid="pone.0190877.t003">Table 3</xref></bold>).</p><p>In contrast, the NAs of B/YAM viruses carrying D342S or A395T NA substitutions had a reduced <italic>V</italic><sub>max</sub> (<italic>P</italic> &#x0003c; 0.05). The higher <italic>V</italic><sub>max</sub> of the influenza A virus NA may facilitate the release and spread of A/PR8-S331G and A/PR8-S331R viruses, but the higher <italic>K</italic><sub>m</sub> indicates that the NA has a low affinity for its substrate. These results suggest that the NA substitutions contribute to the reduction in NA enzymatic activity.</p></sec><sec id="sec015"><title>NA thermostability</title><p>NA amino acid substitutions can contribute to NA protein stability [<xref rid="pone.0190877.ref011" ref-type="bibr">11</xref>]. Therefore, we determined the thermostability of mutant NAs by measuring the NA activity of the recombinant viruses after 15 and 30 min of incubation at different temperatures. For recombinant influenza A viruses, the NA activity of the A/PR8-I222V virus was stable at 33&#x000b0;C to 55&#x000b0;C, whereas the A/PR8-S331G and A/PR8-S331R viruses showed lower activity at 55&#x000b0;C (<bold><xref ref-type="fig" rid="pone.0190877.g001">Fig 1A and 1B</xref></bold>). The NA activity of recombinant B/YAM viruses carrying T/V/D changes at residue 395 and the B/BR/60/08 virus was undetectable after incubation at 55&#x000b0;C. In contrast, virus carrying the D342S NA substitution possessed high NA activity that was thermostable (<bold><xref ref-type="fig" rid="pone.0190877.g001">Fig 1C and 1D</xref></bold>).</p><fig id="pone.0190877.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0190877.g001</object-id><label>Fig 1</label><caption><title>The NA thermostability of the recombinant influenza A and B viruses carrying a single NA substitution.</title><p>Influenza A/PR8 (A, B) and B/YAM (C, D) viruses were incubated for 15 or 30 min at the indicated temperatures. Residual NA enzyme activity was assayed and is presented as a percentage of the NA activity at 4&#x000b0;C (unheated). The bars represent the mean of the relative NA activity &#x000b1; SD for different temperatures from three experiments. *<italic>P</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="pone.0190877.g001"/></fig></sec><sec id="sec016"><title>Replication kinetics</title><p>To evaluate the fitness <italic>in vitro</italic> of recombinant influenza A and B viruses carrying NA amino acid substitutions, we studied their replication capacity in MDCK cells. At 6 and 12 h post-infection (hpi), the growth of A/PR8-I222V virus was similar to that of A/PR8-WT, but the A/PR8-S331G and A/PR8-S331R virus yields were significantly lower (<italic>P</italic> &#x0003c; 0.05) (<bold><xref ref-type="fig" rid="pone.0190877.g002">Fig 2A</xref></bold>). At 48 hpi, the yields of all recombinant influenza A viruses were comparable (range, 6.8&#x02013;7.5 log<sub>10</sub>TCID<sub>50</sub>/mL) (<bold><xref ref-type="fig" rid="pone.0190877.g002">Fig 2B</xref></bold>). At 6 and 12 hpi, the recombinant influenza B virus yields were significantly lower than that of B/BR/60/08 virus (<italic>P</italic> &#x0003c; 0.05) (<bold><xref ref-type="fig" rid="pone.0190877.g002">Fig 2C</xref></bold>). At 48 hpi, all influenza B viruses replicated to significantly higher virus titers in MDCK cells when compared to B/BR/60/08 virus (<italic>P</italic> &#x0003c; 0.05) (<bold><xref ref-type="fig" rid="pone.0190877.g002">Fig 2D</xref></bold>). At 72 hpi, the viral titers of the recombinant influenza B viruses were 4.2 and 5.2 log<sub>10</sub>TCID<sub>50</sub>/mL. These results demonstrated that the NA substitutions S331G and S331R (on an A/PR8 background) and D342S, A395T, A395V, and A395D (on a B/YAM background) reduced the enzyme activity and thermostability of the NA. Although replication ability of recombinant influenza A and B viruses was heterogeneous at early time points, they showed at least equivalent yields as A/PR8-WT and B/BR/60/08 viruses at later time points. However, using B/BR/60/08 instead of the recombinant B/YAM virus with the wild-type NA is a caveat of this comparison.</p><fig id="pone.0190877.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0190877.g002</object-id><label>Fig 2</label><caption><title>Replication kinetics in MDCK cells of recombinant influenza A and B viruses carrying a single NA amino acid substitution.</title><p>MDCK cells were infected with recombinant influenza A and B viruses at an MOI of 1 (A, C) or 0.001 (B, D). Virus titers were determined by TCID<sub>50</sub> assays in MDCK cells after incubation for 72 h at 35&#x000b0;C (for influenza A viruses) or 33&#x000b0;C (for influenza B viruses). Each data point represents the mean virus titer (log<sub>10</sub>TCID<sub>50</sub>/mL) &#x000b1; the SD from three independent experiments. *<italic>P</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="pone.0190877.g002"/></fig></sec><sec id="sec017"><title>NA genetic stability</title><p>To determine whether NA substitutions introduced into the A/PR8 and B/YAM genetic backgrounds could be stably maintained <italic>in vitro</italic>, the NA genes were amplified from viruses before and after three passages in MDCK cells, and the NA sequences were determined. The I222V, S331G, and S331R NA substitutions were genetically stable in NA proteins on the genetic background of the A/PR8 virus. A diverse pattern was observed for influenza B viruses. The A395T and A395D substitutions were genetically stable and were maintained unchanged during three passages, whereas the D342S and A395V substitutions were unstable and the NAs reverted to WT after three passages (<bold><xref ref-type="table" rid="pone.0190877.t004">Table 4</xref></bold>). These findings indicate that genetically unstable D342S and A395V NA substitutions are unlikely to emerge at a high frequency in influenza B viruses.</p><table-wrap id="pone.0190877.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0190877.t004</object-id><label>Table 4</label><caption><title>Genetic stability of NA substitutions among recombinant influenza A and B viruses after three subsequent passages in MDCK cells.</title></caption><alternatives><graphic id="pone.0190877.t004g" xlink:href="pone.0190877.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Recombinant influenza virus</th><th align="left" colspan="2" rowspan="1">Passage in MDCK cells</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">0 passage</th><th align="left" rowspan="1" colspan="1">3<sup>rd</sup> passage</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Influenza A viruses</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-I222V</td><td align="center" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">V</td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-S331G</td><td align="center" rowspan="1" colspan="1">G</td><td align="center" rowspan="1" colspan="1">G</td></tr><tr><td align="left" rowspan="1" colspan="1">A/PR8-S331R</td><td align="center" rowspan="1" colspan="1">R</td><td align="center" rowspan="1" colspan="1">R</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Influenza B viruses</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-D342S</td><td align="center" rowspan="1" colspan="1">S</td><td align="center" rowspan="1" colspan="1">D</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395T</td><td align="center" rowspan="1" colspan="1">T</td><td align="center" rowspan="1" colspan="1">T</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395D</td><td align="center" rowspan="1" colspan="1">D</td><td align="center" rowspan="1" colspan="1">D</td></tr><tr><td align="left" rowspan="1" colspan="1">B/YAM-A395V</td><td align="center" rowspan="1" colspan="1">V</td><td align="center" rowspan="1" colspan="1">A</td></tr></tbody></table></alternatives></table-wrap></sec></sec><sec sec-type="conclusions" id="sec018"><title>Discussion</title><p>In this study, we investigated the effect of novel NA amino acid substitutions on the NAI susceptibility, NA enzymatic properties, and replication capacity of influenza viruses <italic>in vitro</italic>. We generated recombinant (7:1) influenza A and B viruses containing the NA glycoprotein from viruses currently circulating in Thailand on the homogeneous genetic background of A/PR8 and B/YAM viruses for the recombinant influenza A and B viruses, respectively. The conserved I222 framework residue in the NA of influenza virus provides support to the catalytic residues [<xref rid="pone.0190877.ref007" ref-type="bibr">7</xref>]. In our study, the A/PR8-I222V virus was susceptible to NAIs in a phenotypic NA inhibition assay and possessed slightly increased NA enzymatic activity. It was previously reported that an influenza A(H3N2) virus with a single I222V NA amino acid substitution was susceptible to oseltamivir and possessed slightly higher NA enzymatic activity as compared to WT virus [<xref rid="pone.0190877.ref028" ref-type="bibr">28</xref>]. Our data revealed that recombinant A/PR8-I222V virus has only a minor effect on the NA enzymatic properties and virus replication efficiency in MDCK cells. However, the I222V NA substitution has a compensatory effect on the influenza A(H3N2) virus carrying E119V, and the presence of these two substitutions resulted in partially improved viral fitness in cell culture and resistance to oseltamivir [<xref rid="pone.0190877.ref029" ref-type="bibr">29</xref>].</p><p>Regarding the S331G/R, D342S, and A395T/D/V NA amino acid substitutions, these are found outside the NA active site, and viruses with these substitutions showed normal inhibition by NAIs. The S331G and S331R substitutions affected the kinetic properties of the NA enzyme, changing its binding affinity (<italic>K</italic><sub>m</sub>) for MUNANA substrate. The <italic>V</italic><sub>max</sub> of the A/PR8-S331G and A/PR8-S331R virus NAs was nearly double that of the A/PR8-WT NA, demonstrating the compensatory effect as reflected in the lower replication capacity of viruses carrying S331G and S331R substitutions when compared to viruses with WT or I222V NAs. The significant decrease in NA activity and the increased <italic>K</italic><sub>m</sub> value demonstrated that S331G and S331R NA substitutions are deleterious to NA functions. The NA activity of the A/PR8-S331G and A/PR8-S331R viruses was decreased, and their viral titers in MDCK cells were lower than those of the WT virus at 6 and 12 hpi. The A/PR8-S331G and A/PR8-S331R viruses were characterized by a loss of NA activity at higher temperature (55&#x000b0;C), whereas PR8-WT and A/PR8-I222V viruses did not lose their NA activity. These data indicate that the viral replication capacity <italic>in vitro</italic> is dependent on the NA activity and the thermostability of the viruses [<xref rid="pone.0190877.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0190877.ref030" ref-type="bibr">30</xref>]. The B/YAM-D342S, B/YAM-A395T, and B/YAM-A395V viruses showed increased NA activity, whereas their <italic>K</italic><sub>m</sub> and <italic>V</italic><sub>max</sub> values decreased. These data suggest that there is an inverse relationship between NA activity and <italic>K</italic><sub>m</sub> and <italic>V</italic><sub>max</sub> values and that these amino acid substitutions are beneficial to NA functions. Moreover, B/YAM-D342S, B/YAM-A395T, and B/YAM-A395V viruses gave significantly higher viral yields at 48 hpi in MDCK cells, as compared to B/BR/60/08 virus. At higher temperature (55&#x000b0;C), the NA activity of recombinant influenza A viruses carrying NA substitutions was more stable than that of influenza B viruses. The A395V and D342S NA substitutions on the B/YAM background were unstable, and the NAs reverted to WT after three passages <italic>in vitro</italic>.</p><p>There were a few limitations in this study. As we could not generate a recombinant B/YAM virus with WT NA protein by using reverse genetics, we used the B/BR/60/08 virus, which is genetically similar to viruses circulating in Thailand, and compared the NA enzymatic properties and viral replication efficiency <italic>in vitro</italic>. Therefore, our results require validation using the B/YAM-WT NA virus. NAs from influenza A(H3N2) PCR-positive samples with I222V, S331G, and S331R NA substitutions were generated in the A/PR8 (H1N1) backbone. The replication efficiency of these viruses in MDCK cells may differ from that of natural isolates because of the effect of the HA-NA balance [<xref rid="pone.0190877.ref031" ref-type="bibr">31</xref>]. Although we used a validated and standardized method to determine influenza NA enzymatic properties using a whole virus preparation as a source of enzyme [<xref rid="pone.0190877.ref027" ref-type="bibr">27</xref>], this approach has limitations. Standardization of NA content based on TCID<sub>50</sub> does not account for defective/non-infectious virions in the virus preparations, which may be enzymatically active. NA content can be reliably standardized in purified NA proteins; however, protein production on this scale, and when evaluating numerous viruses/proteins, is not readily achievable.</p><p>In conclusion, the recombinant influenza A and B viruses containing different NA substitutions located outside the NA active site exhibited normal inhibition by NAIs but differed in their NA enzymatic properties and their replication capacity <italic>in vitro</italic>. Continuous influenza antiviral surveillance is important for the identification of molecular markers of antiviral resistance and the characterization of NA enzyme functions and viral fitness.</p></sec></body><back><ack><p>We thank Keith A. Laycock, PhD, ELS, for excellent editing of the manuscript and the staff of the Hartwell Center for Bioinformatics and Biotechnology for their help with the Sanger sequencing. The NAIs oseltamivir carboxylate (oseltamivir) and zanamivir were provided by Hoffmann-La Roche, Ltd. (Basel, Switzerland). The NAI peramivir was provided by BioCryst Pharmaceuticals (Birmingham, AL).</p></ack><ref-list><title>References</title><ref id="pone.0190877.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Fiore</surname><given-names>AE</given-names></name>, <name><surname>Fry</surname><given-names>A</given-names></name>, <name><surname>Shay</surname><given-names>D</given-names></name>, <name><surname>Gubareva</surname><given-names>L</given-names></name>, <name><surname>Bresee</surname><given-names>JS</given-names></name>, <name><surname>Uyeki</surname><given-names>TM</given-names></name>; <article-title>Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)</article-title>. <source>MMWR Recomm Rep</source>. <year>2011</year>; <volume>60</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>24</lpage>. <?supplied-pmid 21248682?><pub-id pub-id-type="pmid">21248682</pub-id></mixed-citation></ref><ref id="pone.0190877.ref002"><label>2</label><mixed-citation publication-type="other">Centers for Diseases Control and Prevention. Influenza antiviral medications: summary for clinicians. [Cited 2017 March 29]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/pdf/professionals/antivirals/antiviral-summary-clinician-updated.pdf">https://www.cdc.gov/flu/pdf/professionals/antivirals/antiviral-summary-clinician-updated.pdf</ext-link>.</mixed-citation></ref><ref id="pone.0190877.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Palese</surname><given-names>P</given-names></name>, <name><surname>Tobita</surname><given-names>K</given-names></name>, <name><surname>Ueda</surname><given-names>M</given-names></name>, <name><surname>Compans</surname><given-names>RW</given-names></name>. <article-title>Characterization of temperature sensitive influenza virus mutants defective in neuraminidase</article-title>. <source>Virology</source>
<year>1974</year>; <volume>61</volume>(<issue>2</issue>):<fpage>397</fpage>&#x02013;<lpage>410</lpage>. <?supplied-pmid 4472498?><pub-id pub-id-type="pmid">4472498</pub-id></mixed-citation></ref><ref id="pone.0190877.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Shi</surname><given-names>W</given-names></name>, <name><surname>Qiao</surname><given-names>H</given-names></name>, <name><surname>Ho</surname><given-names>SY</given-names></name>, <name><surname>Luo</surname><given-names>A</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Positive selection on hemagglutinin and neuraminidase genes of H1N1 influenza viruses</article-title>. <source>Virol J</source>. <year>2011</year>; <volume>8</volume>:<fpage>183</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1743-422X-8-183">10.1186/1743-422X-8-183</ext-link></comment>
<?supplied-pmid 21507270?><pub-id pub-id-type="pmid">21507270</pub-id></mixed-citation></ref><ref id="pone.0190877.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Gamblin</surname><given-names>SJ</given-names></name>, <name><surname>Skehel</surname><given-names>JJ</given-names></name>. <article-title>Influenza hemagglutinin and neuraminidase membrane glycoproteins</article-title>. <source>J Biol Chem</source>. <year>2010</year>; <volume>285</volume>(<issue>37</issue>):<fpage>28403</fpage>&#x02013;<lpage>28409</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.R110.129809">10.1074/jbc.R110.129809</ext-link></comment>
<?supplied-pmid 20538598?><pub-id pub-id-type="pmid">20538598</pub-id></mixed-citation></ref><ref id="pone.0190877.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Colman</surname><given-names>PM</given-names></name>, <name><surname>Varghese</surname><given-names>JN</given-names></name>, <name><surname>Laver</surname><given-names>WG</given-names></name>. <article-title>Structure of the catalytic and antigenic sites in influenza virus neuraminidase</article-title>. <source>Nature</source>
<year>1983</year>; <volume>303</volume>(<issue>5912</issue>):<fpage>41</fpage>&#x02013;<lpage>44</lpage>. <?supplied-pmid 6188957?><pub-id pub-id-type="pmid">6188957</pub-id></mixed-citation></ref><ref id="pone.0190877.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Burmeister</surname><given-names>WP</given-names></name>, <name><surname>Ruigrok</surname><given-names>RW</given-names></name>, <name><surname>Cusack</surname><given-names>S</given-names></name>. <article-title>The 2.2 &#x000c5; resolution crystal structure of influenza B neuraminidase and its complex with sialic acid</article-title>. <source>EMBO J</source>. <year>1992</year>; <volume>11</volume>(<issue>1</issue>):<fpage>49</fpage>&#x02013;<lpage>56</lpage>. <?supplied-pmid 1740114?><pub-id pub-id-type="pmid">1740114</pub-id></mixed-citation></ref><ref id="pone.0190877.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Colman</surname><given-names>PM</given-names></name>, <name><surname>Hoyne</surname><given-names>PA</given-names></name>, <name><surname>Lawrence</surname><given-names>MC</given-names></name>. <article-title>Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase</article-title>. <source>J Virol</source>. <year>1993</year>; <volume>67</volume>(<issue>6</issue>):<fpage>2972</fpage>&#x02013;<lpage>2980</lpage>. <?supplied-pmid 8497041?><pub-id pub-id-type="pmid">8497041</pub-id></mixed-citation></ref><ref id="pone.0190877.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Yen</surname><given-names>HL</given-names></name>, <name><surname>Hoffmann</surname><given-names>E</given-names></name>, <name><surname>Taylor</surname><given-names>G</given-names></name>, <name><surname>Scholtissek</surname><given-names>C</given-names></name>, <name><surname>Monto</surname><given-names>AS</given-names></name>, <name><surname>Webster</surname><given-names>RG</given-names></name>, <etal>et al</etal>
<article-title>Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses</article-title>. <source>J Virol</source>. <year>2006</year>; <volume>80</volume>(<issue>17</issue>):<fpage>8787</fpage>&#x02013;<lpage>8795</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.00477-06">10.1128/JVI.00477-06</ext-link></comment>
<?supplied-pmid 16912325?><pub-id pub-id-type="pmid">16912325</pub-id></mixed-citation></ref><ref id="pone.0190877.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Nguyen</surname><given-names>HT</given-names></name>, <name><surname>Fry</surname><given-names>AM</given-names></name>, <name><surname>Gubareva</surname><given-names>LV</given-names></name>. <article-title>Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods</article-title>. <source>Antivir Ther</source>. <year>2012</year>; <volume>17</volume>(<issue>1 Pt B</issue>):<fpage>159</fpage>&#x02013;<lpage>173</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3851/IMP2067">10.3851/IMP2067</ext-link></comment>
<?supplied-pmid 22311680?><pub-id pub-id-type="pmid">22311680</pub-id></mixed-citation></ref><ref id="pone.0190877.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Burnham</surname><given-names>AJ</given-names></name>, <name><surname>Baranovich</surname><given-names>T</given-names></name>, <name><surname>Govorkova</surname><given-names>EA</given-names></name>. <article-title>Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance</article-title>. <source>Antiviral Res</source>. <year>2013</year>; <volume>100</volume>(<issue>2</issue>):<fpage>520</fpage>&#x02013;<lpage>534</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.antiviral.2013.08.023">10.1016/j.antiviral.2013.08.023</ext-link></comment>
<?supplied-pmid 24013000?><pub-id pub-id-type="pmid">24013000</pub-id></mixed-citation></ref><ref id="pone.0190877.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Govorkova</surname><given-names>EA</given-names></name>. <article-title>Consequences of resistance: in vitro fitness, in vivo infectivity, and transmissibility of oseltamivir-resistant influenza A viruses</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2013</year>;<volume>7</volume>
<issue>Suppl 1</issue>:<fpage>50</fpage>&#x02013;<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/irv.12044">10.1111/irv.12044</ext-link></comment>
<?supplied-pmid 23279897?><pub-id pub-id-type="pmid">23279897</pub-id></mixed-citation></ref><ref id="pone.0190877.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>McKimm-Breschkin</surname><given-names>JL</given-names></name>, <name><surname>Barrett</surname><given-names>S</given-names></name>, <name><surname>Pudjiatmoko, Azhar</surname><given-names>M</given-names></name>, <name><surname>Wong</surname><given-names>FY</given-names></name>, <name><surname>Selleck</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>I222 neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian clade 2.1 highly pathogenic avian influenza A(H5N1) viruses</article-title>. <source>PLoS One</source>. <year>2013</year>; <volume>8</volume>(<issue>6</issue>):<fpage>e66105</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0066105">10.1371/journal.pone.0066105</ext-link></comment>
<?supplied-pmid 23776615?><pub-id pub-id-type="pmid">23776615</pub-id></mixed-citation></ref><ref id="pone.0190877.ref014"><label>14</label><mixed-citation publication-type="other">WHO. Weekly epidemiological record (WER). 2012; 87(39):369&#x02013;380. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/wer/2012/wer8739/en/">http://www.who.int/wer/2012/wer8739/en/</ext-link>.</mixed-citation></ref><ref id="pone.0190877.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Leang</surname><given-names>SK</given-names></name>, <name><surname>Kwok</surname><given-names>S</given-names></name>, <name><surname>Sullivan</surname><given-names>SG</given-names></name>, <name><surname>Maurer-Stroh</surname><given-names>S</given-names></name>, <name><surname>Kelso</surname><given-names>A</given-names></name>, <name><surname>Barr</surname><given-names>IG</given-names></name>, <etal>et al</etal>
<article-title>Peramivir and laninamivir susceptibility of circulating influenza A and B viruses</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2014</year>; <volume>8</volume>(<issue>2</issue>):<fpage>135</fpage>&#x02013;<lpage>139</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/irv.12187">10.1111/irv.12187</ext-link></comment>
<?supplied-pmid 24734292?><pub-id pub-id-type="pmid">24734292</pub-id></mixed-citation></ref><ref id="pone.0190877.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Hurt</surname><given-names>AC</given-names></name>, <name><surname>Besselaar</surname><given-names>TG</given-names></name>, <name><surname>Daniels</surname><given-names>RS</given-names></name>, <name><surname>Ermetal</surname><given-names>B</given-names></name>, <name><surname>Fry</surname><given-names>A</given-names></name>, <name><surname>Gubareva</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014&#x02013;2015</article-title>. <source>Antiviral Res</source>. <year>2016</year>; <volume>132</volume>:<fpage>178</fpage>&#x02013;<lpage>185</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.antiviral.2016.06.001">10.1016/j.antiviral.2016.06.001</ext-link></comment>
<?supplied-pmid 27265623?><pub-id pub-id-type="pmid">27265623</pub-id></mixed-citation></ref><ref id="pone.0190877.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Leang</surname><given-names>SK</given-names></name>, <name><surname>Deng</surname><given-names>YM</given-names></name>, <name><surname>Shaw</surname><given-names>R</given-names></name>, <name><surname>Caldwell</surname><given-names>N</given-names></name>, <name><surname>Iannello</surname><given-names>P</given-names></name>, <name><surname>Komadina</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Influenza antiviral resistance in the Asia-Pacific region during 2011</article-title>. <source>Antiviral Res</source>. <year>2013</year>; <volume>97</volume>(<issue>2</issue>):<fpage>206</fpage>&#x02013;<lpage>210</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.antiviral.2012.12.016">10.1016/j.antiviral.2012.12.016</ext-link></comment>
<?supplied-pmid 23274624?><pub-id pub-id-type="pmid">23274624</pub-id></mixed-citation></ref><ref id="pone.0190877.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Tu</surname><given-names>V</given-names></name>, <name><surname>Abed</surname><given-names>Y</given-names></name>, <name><surname>Barbeau</surname><given-names>X</given-names></name>, <name><surname>Carbonneau</surname><given-names>J</given-names></name>, <name><surname>Fage</surname><given-names>C</given-names></name>, <name><surname>Lag&#x000fc;e</surname><given-names>P</given-names></name>, <name><surname>Boivin</surname><given-names>G</given-names></name>. <article-title>The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness</article-title>. <source>Antiviral Res</source>. <year>2017</year>; <volume>137</volume>:<fpage>6</fpage>&#x02013;<lpage>1313</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.antiviral.2016.11.007">10.1016/j.antiviral.2016.11.007</ext-link></comment>
<?supplied-pmid 27838351?><pub-id pub-id-type="pmid">27838351</pub-id></mixed-citation></ref><ref id="pone.0190877.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Tewawong</surname><given-names>N</given-names></name>, <name><surname>Vichiwattana</surname><given-names>P</given-names></name>, <name><surname>Korkong</surname><given-names>S</given-names></name>, <name><surname>Klinfueng</surname><given-names>S</given-names></name>, <name><surname>Suntronwong</surname><given-names>N</given-names></name>, <name><surname>Thongmee</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Evolution of the neuraminidase gene of seasonal influenza A and B viruses in Thailand between 2010 and 2015</article-title>. <source>PLoS One</source>. <year>2017</year>; <volume>12</volume>(<issue>4</issue>):<fpage>e0175655</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0175655">10.1371/journal.pone.0175655</ext-link></comment>
<?supplied-pmid 28410396?><pub-id pub-id-type="pmid">28410396</pub-id></mixed-citation></ref><ref id="pone.0190877.ref020"><label>20</label><mixed-citation publication-type="other">The WHO GISRS Antiviral Susceptibility Expert Working Group (AVWG). Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). Last updated 21 October 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/avwg2014_nai_substitution_table.pdf?ua=1">http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/avwg2014_nai_substitution_table.pdf?ua=1</ext-link>.</mixed-citation></ref><ref id="pone.0190877.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>E</given-names></name>, <name><surname>Stech</surname><given-names>J</given-names></name>, <name><surname>Guan</surname><given-names>Y</given-names></name>, <name><surname>Webster</surname><given-names>RG</given-names></name>, <name><surname>Perez</surname><given-names>DR</given-names></name>. <article-title>Universal primer set for the full-length amplification of all influenza A viruses</article-title>. <source>Arch Virol</source>. <year>2001</year>; <volume>146</volume>(<issue>12</issue>):<fpage>2275</fpage>&#x02013;<lpage>2289</lpage>. <?supplied-pmid 11811679?><pub-id pub-id-type="pmid">11811679</pub-id></mixed-citation></ref><ref id="pone.0190877.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>E</given-names></name>, <name><surname>Mahmood</surname><given-names>K</given-names></name>, <name><surname>Yang</surname><given-names>CF</given-names></name>, <name><surname>Webster</surname><given-names>RG</given-names></name>, <name><surname>Greenberg</surname><given-names>HB</given-names></name>, <name><surname>Kemble</surname><given-names>G</given-names></name>. <article-title>Rescue of influenza B virus from eight plasmids</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2002</year>; <volume>99</volume>(<issue>17</issue>):<fpage>11411</fpage>&#x02013;<lpage>11416</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.172393399">10.1073/pnas.172393399</ext-link></comment>
<?supplied-pmid 12172012?><pub-id pub-id-type="pmid">12172012</pub-id></mixed-citation></ref><ref id="pone.0190877.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>E</given-names></name>, <name><surname>Neumann</surname><given-names>G</given-names></name>, <name><surname>Kawaoka</surname><given-names>Y</given-names></name>, <name><surname>Hobom</surname><given-names>G</given-names></name>, <name><surname>Webster</surname><given-names>RG</given-names></name>. <article-title>A DNA transfection system for generation of influenza A virus from eight plasmids</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2000</year>; <volume>97</volume>(<issue>11</issue>):<fpage>6108</fpage>&#x02013;<lpage>6113</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.100133697">10.1073/pnas.100133697</ext-link></comment>
<?supplied-pmid 10801978?><pub-id pub-id-type="pmid">10801978</pub-id></mixed-citation></ref><ref id="pone.0190877.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Reed</surname><given-names>LJ</given-names></name>, <name><surname>Muench</surname><given-names>H</given-names></name>. <article-title>A simple method for estimating fifty percent endpoints</article-title>. <source>Am J Hyg</source>. <year>1938</year>; <volume>27</volume>:<fpage>493</fpage>&#x02013;<lpage>497</lpage>.</mixed-citation></ref><ref id="pone.0190877.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Gubareva</surname><given-names>LV</given-names></name>, <name><surname>Webster</surname><given-names>RG</given-names></name>, <name><surname>Hayden</surname><given-names>FG</given-names></name>. <article-title>Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay</article-title>. <source>Antiviral Res</source>. <year>2002</year>; <volume>53</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>61</lpage>. <?supplied-pmid 11684315?><pub-id pub-id-type="pmid">11684315</pub-id></mixed-citation></ref><ref id="pone.0190877.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Potier</surname><given-names>M</given-names></name>, <name><surname>Mameli</surname><given-names>L</given-names></name>, <name><surname>B&#x000e9;lisle</surname><given-names>M</given-names></name>, <name><surname>Dallaire</surname><given-names>L</given-names></name>, <name><surname>Melan&#x000e7;on</surname><given-names>SB</given-names></name>. <article-title>Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate</article-title>. <source>Anal Biochem</source>. <year>1979</year>; <volume>94</volume>(<issue>2</issue>):<fpage>287</fpage>&#x02013;<lpage>296</lpage>. <?supplied-pmid 464297?><pub-id pub-id-type="pmid">464297</pub-id></mixed-citation></ref><ref id="pone.0190877.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Marathe</surname><given-names>BM</given-names></name>, <name><surname>L&#x000e9;v&#x000ea;que</surname><given-names>V</given-names></name>, <name><surname>Klumpp</surname><given-names>K</given-names></name>, <name><surname>Webster</surname><given-names>RG</given-names></name>, <name><surname>Govorkova</surname><given-names>EA</given-names></name>. <article-title>Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>:<fpage>e71401</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0071401">10.1371/journal.pone.0071401</ext-link></comment>
<?supplied-pmid 23977037?><pub-id pub-id-type="pmid">23977037</pub-id></mixed-citation></ref><ref id="pone.0190877.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Baz</surname><given-names>M</given-names></name>, <name><surname>Abed</surname><given-names>Y</given-names></name>, <name><surname>McDonald</surname><given-names>J</given-names></name>, <name><surname>Boivin</surname><given-names>G</given-names></name>. <article-title>Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>; <volume>43</volume>(<issue>12</issue>):<fpage>1555</fpage>&#x02013;<lpage>15561</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/508777">10.1086/508777</ext-link></comment>
<?supplied-pmid 17109288?><pub-id pub-id-type="pmid">17109288</pub-id></mixed-citation></ref><ref id="pone.0190877.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Simon</surname><given-names>P</given-names></name>, <name><surname>Holder</surname><given-names>BP</given-names></name>, <name><surname>Bouhy</surname><given-names>X</given-names></name>, <name><surname>Abed</surname><given-names>Y</given-names></name>, <name><surname>Beauchemin</surname><given-names>CA</given-names></name>, <name><surname>Boivin</surname><given-names>G</given-names></name>. <article-title>The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant</article-title>. <source>J Clin Microbiol</source>. <year>2011</year>;<volume>49</volume>(<issue>2</issue>):<fpage>715</fpage>&#x02013;<lpage>717</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JCM.01732-10">10.1128/JCM.01732-10</ext-link></comment>
<?supplied-pmid 21106781?><pub-id pub-id-type="pmid">21106781</pub-id></mixed-citation></ref><ref id="pone.0190877.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Burnham</surname><given-names>AJ</given-names></name>, <name><surname>Baranovich</surname><given-names>T</given-names></name>, <name><surname>Marathe</surname><given-names>BM</given-names></name>, <name><surname>Armstrong</surname><given-names>J</given-names></name>, <name><surname>Webster</surname><given-names>RG</given-names></name>, <name><surname>Govorkova</surname><given-names>EA</given-names></name>. <article-title>Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>; <volume>58</volume>(<issue>5</issue>):<fpage>2718</fpage>&#x02013;<lpage>2730</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.02628-13">10.1128/AAC.02628-13</ext-link></comment>
<?supplied-pmid 24566185?><pub-id pub-id-type="pmid">24566185</pub-id></mixed-citation></ref><ref id="pone.0190877.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Little</surname><given-names>K</given-names></name>, <name><surname>Leang</surname><given-names>SK</given-names></name>, <name><surname>Butler</surname><given-names>J</given-names></name>, <name><surname>Baas</surname><given-names>C</given-names></name>, <name><surname>Harrower</surname><given-names>B</given-names></name>, <name><surname>Mosse</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring</article-title>. <source>Euro Surveill</source>. <year>2015</year>; <volume>20</volume>(<issue>45</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2807/1560-7917.ES.2015.20.45.30060">10.2807/1560-7917.ES.2015.20.45.30060</ext-link></comment>
<?supplied-pmid 26608955?><pub-id pub-id-type="pmid">26608955</pub-id></mixed-citation></ref></ref-list></back></article>